In general, our results suggested that targeting DLK1 might inhibit the tumor growth via initiating cell differentiation of HCC CSCs, although molecular mechanisms by which DLK1 knockdown contributes differentiation therapy of HCC should be further investigated. The gene discussed is DLK1; the disease is neoplasm.